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The purpose of this study was to evaluate the role of the epidermal growth factor receptor (EGFR) in parathyroid hormone-related
protein (PTHrP) expression and humoral hypercalcaemia of malignancy (HHM), using two different human squamous-cell carcinoma
(SCC) xenograft models. A randomised controlled study in which nude mice with RWGT2 and HARA xenografts received either
placebo or gefitinib 200mgkg
 1 for 3 days after developing HHM. Effectiveness of therapy was evaluated by measuring plasma
calcium and PTHrP, urine cyclic AMP/creatinine ratios, and tumour volumes. The study end point was at 78h. The lung SCC lines,
RWGT2 and HARA, expressed high levels of PTHrP mRNA as well as abundant EGFR protein, but very little erbB2 or erbB3. Both
lines expressed high transcript levels for the EGFR ligand, amphiregulin (AREG), as well as, substantially lower levels of transforming
growth factor-a (TGF-a), and heparin binding-epidermal growth factor (HB-EGF) mRNA. Parathyroid hormone-related protein gene
expression in both lines was reduced 40–80% after treatment with 1mM of EGFR tyrosine kinase inhibitor PD153035 and
precipitating antibodies to AREG. Gefitinib treatment of hypercalcaemic mice with RWGT2 and HARA xenografts resulted in a
significant reduction of plasma total calcium concentrations by 78h. Autocrine AREG stimulated the EGFR and increased PTHrP gene
expression in the RWGT2 and HARA lung SCC lines. Inhibition of the EGFR pathway in two human SCC models of HHM by an
anilinoquinazoline demonstrated that the EGFR tyrosine kinase is a potential target for antihypercalcaemic therapy.
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Humoral hypercalcaemia of malignancy is a paraneoplastic
disorder commonly associated with increased synthesis and
secretion of parathyroid hormone-related protein (PTHrP) (Burtis
et al, 1988). Studies from industrialised nations in the 1970s and
1980s, as well as more recent studies from other countries, report
that patients with squamous-cell carcinoma (SCC) of the lung have
the highest frequency of humoral hypercalcaemia of malignancy
(HHM; ranging from 27 to 66%) as compared to other tumour
types (Bender and Hansen, 1974; Mundy and Martin, 1982;
Lazaretti-Castro et al, 1993). The precise mechanisms that activate
high levels of PTHrP gene expression in tumours that are
associated with HHM have yet to be identified. The diagnosis of
HHM has a poor prognosis with a survival of less than 3 months
(Wimalawansa, 1994). Hypercalcaemia has clinical effects on
multiple organs such as fatigue, psychosis, confusion, vomiting,
renal failure, constipation and cardiac arrest, which become life
threatening as the syndrome progresses.
The ErbB pathway genes, especially the epidermal growth factor
receptor (EGFR), are frequently overexpressed in SCC of the lung
(Franklin et al, 2002). Lung SCCs produce a wide range of
cytokines and growth factors, including those of the epidermal
growth factor (EGF) family, such as transforming growth factor-a
(TGF-a) and amphiregulin (AREG) (Rusch et al, 1993; Piyathilake
et al, 2002). Activation of EGFR cytoplasmic receptor tyrosine
kinases regulate essential cellular functions including proliferation,
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ssurvival, migration, and differentiation, and play a central role in
the genesis and progression of solid tumours (Jorissen et al, 2003).
The prominent role of EGFR signalling in many tumour types has
prompted the development of pharmacological inhibitors such as
the anilinoquinazolines (gefitinib and erlotinib), which disrupt
EGFR kinase activity by binding the ATP pocket within the
catalytic kinase domain (Wakeling, 2002). Gefitinib induced
substantial clinical responses and reduced tumour burden in
B10% of patients with chemotherapy–refractory non-small cell
lung cancers; however, the majority of these patients had EGFR
mutations that constitutively activated the antiapoptotic protein
AKT (Baselga, 2002; Fukuoka et al, 2003; Kris et al, 2003; Giaccone
et al, 2004). Also, a phase III survival trial failed to verify the
clinical benefit of gefitinib treatment for non-small cell lung cancer
patients. In contrast, a phase III trial evaluating erlotinib efficacy
revealed a significant overall improved survival rate for all non-
small cell lung cancer patients (Tsao et al, 2005). In the future,
EGFR-targeted therapeutics may be routinely used in the treatment
of non-small cell lung cancers, including SCCs.
Parathyroid hormone-related protein is a gene product regu-
lated by EGFR that influences the pathogenesis of lung SCCs.
Previously, we have demonstrated that autocrine stimulation of the
EGFR pathway is a major activator of PTHrP gene expression in
keratinocytes, and disruption of the EGFR in keratinocytes with
the EGFR-tyrosine kinase inhibitor (TKI), PD153035 (PD), reduced
PTHrP mRNA up to 80% (Cho et al, 2004). The role of EGFR
signalling in the stimulation of PTHrP expression and subsequent
development of HHM in patients with SCC of the lung is unknown.
Extensive work on several human cancer lines suggests that
activation of the Ras-mitogen-activated protein kinase (Ras-
MAPK) pathway provides a general mechanism for activation of
PTHrP gene expression (Li and Drucker, 1994; Aklilu et al, 1997,
2000). The Ras-MAPK pathway is regarded as the prototypic
second messenger cascade downstream of EGFR (Yarden, 2001).
We hypothesised that EGFR-induced Ras-MAPK signalling ac-
counts for high levels of PTHrP expression, and contributes to
HHM caused by lung SCC and the administration of EGFR
receptor TKIs would decrease total plasma calcium concentrations.
In this study, we report the expression of the ErbB family of
receptors and the endogenous production of EGFR ligand mRNA
by two human lung SCC cell lines, RWGT2 and HARA, that have
been reported previously to produce hypercalcaemia in athymic
mice (Guise et al, 1993; Iguchi et al, 1996). We present evidence
that autocrine stimulation of the EGFR pathway is a major
contributor to PTHrP gene expression in both lines grown in vitro.
Next, we compared EGFR signalling and PTHrP production in
hypercalcaemic mice with HARA and RWGT2 xenografts. Finally,
we demonstrated that administration of gefitinib reduced hyper-
calcaemia and decreased PTHrP production in both xenograft
models.
MATERIALS AND METHODS
Cell lines, kinase inhibitors and antibodies
RWGT2 cells were obtained from G Mundy and T Guise
(University of Texas Health Science Center, San Antonio, TX,
USA) and maintained in high glucose Dulbecco’s modified Eagle’s
medium with GlutaMaxt (Gibco, Invitrogen, Carlsbad, CA, USA),
supplemented with 10% heat-inactivated fetal bovine serum, and
Normocint 100mgml
 1 (InvivoGen, San Diego, CA, USA). The
HARA cell line was obtained from Dr Haruo Iguchi (Shikoku
Cancer Center, Matsuyama, Japan). The original patient had an
increased PTHrP concentration and hypercalcaemia, but no
apparent bone metastases. HARA cells were maintained as
described for the RWGT2 cells. Cells were passaged at 90%
confluence. In vitro experiments were performed when both
RWGT2 cells and HARA were B90% confluent. For the in vitro
kinase inhibitor assays, the TKIs, PD (Calbiochem, San Diego, CA,
USA) and gefitinib (gift from AstraZeneca, London, UK), as well as
the MEK inhibitor PD98059 (Calbiochem) were dissolved in
dimethylsulphoxide (DMSO), stored at  201C at a stock concen-
tration of 2mM, and used at a final concentration of 1mM. The
drugs were added to cells for 6h and control cells were treated with
media containing 0.01% DMSO (vehicle). For the ligand and EGFR
blocking studies, the anti-human goat AREG antibody (R&D
Systems, Minneapolis, MN, USA) was resuspended in sterile
phosphate-buffered saline (PBS) to yield a final concentration of
100mgml
 1. Both the anti-human EGFR blocking monoclonal
antibody 225 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and anti-AREG antibody were used at 10mgml
 1 and cells were
treated overnight. For the animal studies, gefitinib was purchased
from a national corporate pharmacy.
For immunoblot analysis and/or immunoprecipitations, the
following antibodies were used: Phospho-EGF receptor-Tyr1068
catalogue no. 2234, EGFR no. 2232, erbB2 no. 2242, phospho-p44/
42 mitogen-activated protein kinase (MAPK; Thr202/Tyr204) no.
9101, p44/42 MAPK no. 9102 (Cell Signaling, Beverly, MA, USA),
4G10 anti-phosphotyrosine no. 06–427 (Upstate USA, Charlottes-
ville, VA, USA), erbB3 (sc-285), erbB4 (sc-283) (Santa Cruz
Biotechnology) and anti-b-actin (Sigma, St Louis, MO, USA).
Xenografts in nude (Foxn1
nu) mice, biochemical analysis
and gefitinib administration
All experimental procedures were approved by The Ohio State
University Institutional Laboratory Animal Care and Use Com-
mittee. After baseline blood and urine samples were collected, mice
were preconditioned to avidly consume peanut butter by several
0.25g offerings before tumour development. Six- to eight-week-old
weight-matched (24–26g) male Foxn1
nu nude mice (Harlan,
Indianapolis, IN, USA) were injected subcutaneously over the
dorsal scapular area with 1 10
6 RWGT2 or HARA cells.
Subcutaneous tumours were observable approximately 7 days
after injection.
Animals were monitored and weighed every other day and when
any of the following conditions occurred: (1) tumours were greater
than X1cm
3; (2) cancer-induced loss of muscle mass; or (3) body
weight decreased by X5%, total calcium concentrations were
measured to determine if the mice were hypercalcaemic. Blood
collection was performed via puncture of the mandibular facial
artery or vein with a 22-gauge needle and collected into a
microtainer tube with lithium heparin (Becton Dickinson and
Company, Franklin Lakes, NJ, USA). Plasma total calcium
concentrations were measured in 10ml of heparinised plasma using
the Vitros DT-60 II clinical chemistry analyser (Johnson & Johnson,
Cornilla, GA, USA). Animals were considered hypercalcaemic when
total plasma calcium concentrations were X12mgdl
 1.
Once hypercalcaemia was confirmed, mice were randomly
allocated to treatment with: (a) 200mgkg
 1 of gefitinib (tablet
formulation; AstraZeneca, London, UK) in peanut butter daily for
three consecutive days (0, 24 and 48h) or; (b) 0.25g peanut butter
for three consecutive days (0, 24 and 48h). They were randomised
into two groups such that there was no difference in the mean
plasma total calcium values between the two at the time treatment
was initiated. During treatment, mice were placed in a cage devoid
of mouse chow and bedding and observed until the mixture of
drug and peanut butter or peanut butter alone had been
completely consumed, approximately 2min. Blood (75ml) was
collected to measure plasma total calcium concentrations at 0, 6,
24, 52 and 78h from treated and control mice. As additional
controls, two groups of nontumour-bearing mice were treated as
above in (a) and (b). Urine was collected following spontaneous
voiding on wax paper. To calculate cyclic AMP (cAMP):creatinine
ratios, urine samples (100ml) were collected from mice before
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sxenografting for baseline analysis and at pretreatment and 6, 24, 52
and 78h after treatment with gefitinib. Urine was acidified by
adding 10mlo f6N HCl and stored at  801C until analysis. Tumour
diameters were serially measured with digital calipers, and tumour
volumes were calculated by the formula: volume¼width
2 length/
2. At the 78h time point, mice were killed with 70% compressed
CO2 gas and tumour tissue was collected, weighed, snap-frozen in
liquid nitrogen, and stored at  801C for protein analysis.
Urine cAMP and creatinine assays
Urine samples were diluted 1:2000 in 0.1 N HCl and cAMP levels
were measured using a commercial enzyme immunosorbent assay
kit (Assay Designs, Ann Arbor, MI, USA). Urine cAMP was
normalised to creatinine concentrations, which was measured
using a commercial microplate Jaffe ` reaction kit (Quanti Chrom
Creatinine Assay, BioAssay Systems, Hayward, CA, USA).
Measurements of PTHrP concentrations
To determine the effects of gefitinib on plasma PTHrP concentra-
tions, blood samples were collected via mandibular puncture into
microtainer tubes with lithium heparin (Becton Dickinson and
Company) on ice. A 200ml sample of plasma was obtained from
individual mice for each time point. Plasma PTHrP was measured
at baseline (i.e., before xenografting) (n¼17 RWGT2 and n¼10
HARA mice) and 6 and 78h after the initial treatment with
gefitinib or placebo. Biologically active plasma PTHrP (1–86) was
measured using a commercially available two-site immunoradio-
metric assay (Diagnostic Systems Laboratories Inc., Webster, TX,
USA). The limit for detection of the assay was 0.3pM.
RNA isolation and quantitative real-time reverse
transcriptase PCR
Total RNA was prepared using the Mini RNA Isolation II kit
(Zymo, Orange, CA, USA) according to the manufacturer’s
instructions. Reverse transcription and quantitative real-time
PCR (QRT-PCR) were performed as detailed by Cho et al (2004)
for all transcripts of PTHrP, AREG, TGF-a and HB-EGF. Data were
normalised by use of the ratio of the target cDNA concentration to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to correct
for differences in RNA quantity between samples. The results
represented in the figures were derived from experiments where
the cDNAs were prepared at the same time and then analysed by
QRT-PCR performed on one plate.
Immunoblot analysis
Immunoblotting for erbB and extracellular signal-regulated kinase
(ERK) proteins was performed as in Gilmore and Riese (2004) and
Foley et al (2000).
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Figure 1 RWGT2 and HARA cells express predominately EGFR and ErbB2 receptors and produce EGF-related ligand mRNA for AREG, TGF-a and HB-
EGF. (A) Parathyroid hormone-related protein/GAPDH mRNA ratios in RWGT2 and HARA cell cultures measured by QRT-PCR. The relative ratios of
PTHrP mRNA to GAPDH mRNA levels were expressed as mean7s.e.m. of four cultures from a single experiment. *P¼0.003. (B) Relative epidermal
growth factor family receptor expression as detected by western blots of cell extracts from RWGT2, HARA and the breast cancer cell line MCF-7. The right
side of the figure indicates the specific erbB receptor antibodies. Protein extracts were precipitated using conA as indicated by ppt ConA on lower panel of
the figure. (C, D) AREG, TGF-a, and HB-EGF/GAPDH mRNA ratios in RWGT2 and HARA cultures were measured by QRT-PCR. The relative ratios of
EGF-like ligand mRNA to GAPDH mRNA level were expressed as mean7s.e.m. of four cultures from a single experiment. Note that the y axis for AREG
mRNA is 100-fold greater than the y axis for TGF-a and HB-EGF mRNA. (E) Phosphorylation of the EGFR was measured in extracts from cells grown in
basal medium. The band labelled with phosphotyrosine antibody reactivity was increased with EGF treatment (EGF). The general phosphotyrosine antibody
4G10 and EGFR antibodies used for protein detection are indicated on the right. These experiments were repeated four times with cells derived from
independent passages with similar results.
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sFor measurement of phosphorylation of MAPK, RWGT2 cells
were seeded at a density of 5 10
5 cells/100-mm dish 24h before
treatment with PD. After treatment, cells were washed with ice-
cold PBS, lysed with the protein extraction buffer as above for the
tumour lysates, protein concentration determined, resolved by
sodium dodecyl sulphate-polyacrylamide gel electrophoresis,
transferred to nitrocellulose, and subjected to immunoblot analysis
as described previously.
Transient transfection
Transient transfection was performed using Lipofectamine and
Plus reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Transfections were normalised to
total protein. Otherwise, details are similar to Cho et al (2004).
Total protein was measured with the BCA protein assay reagent kit
(Pierce Biotechnology, Rockford, IL, USA). Results were reported
as relative luciferase units (RLUs), which represent normalised
luciferase values for the Ras and Raf co-transfections divided by
the normalised luciferase value of the empty vector co-transfec-
tions.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labelling staining
Apoptosis was detected utilising the In situ Cell Death Fluorescein
Detection Kit (Roche Diagnostics, Mannheim, Germany). Briefly,
after deparaffinisation, rehydration and washing in 1 PBS,
sections were treated with terminal deoxynucleotidyl transferase
(TdT) enzyme mixture, covered and incubated in a humidified
slide chamber for 60min at 371C in the dark. After fixation,
positive control slides were permeabilised with DNase I for 10min
at 201C to induce DNA strand breaks, before labelling procedures.
The negative control slides were incubated with label solution
without terminal transferase. Finally, the slides were rinsed three
times in PBS and analysed under a fluorescence microscope using
an excitation wavelength of 488nm.
Statistics
Results were expressed as the mean7s.e.m. of triplicate or
quadruplicate measures. Unless specifically indicated statistical
comparisons were based on two-tailed analysis of the Student’s
t-test. A probability value of Po0.05 was considered to be
significant. Analysis of variances (ANOVAs) with repeated
measures were used to analyse the time differences between
groups. Plots with the variable time (baseline, pretreatment, 6, 24,
52 and 78h) in the x axis are reported to show the trends over time.
RESULTS
Stimulation of the EGFR activates PTHrP gene expression
in two hypercalcaemia inducing SCC lines
The RWGT2 cell line was derived from a human lung SCC bone
metastasis and the HARA cell line from a human primary lung SCC
(Guise et al, 1993; Iguchi et al, 1996). At greater than 90%
confluence, RWGT2 cells produce very high levels of all transcripts
of PTHrP (close to 10
6 copies per 2mg of cDNA) as detected by
QRT-PCR (Figure 1A). In comparison, HARA cells at 90%
confluence produced a PTHrP/GADPH mRNA ratio that was less
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Figure 2 Parathyroid hormone-related protein mRNA expression is
reduced by EGFR inhibitors and increased by the addition of exogenous
EGFR ligands. (A) RWGT2 cells were treated with 1mM PD for 6h, a
neutralising polyclonal antibody to AREG (10mgml
 1), a ligand blocking
EGFR antibody (aEGFR, 10mgml
 1) or PBS (C) for 24h. Neutralising
antibodies to growth factors are represented by the symbol (a). The
mRNA was harvested from four independent cultures and analysed by
QRT-PCR. PD, P¼0.03; aAREG, P¼0.05. (B) HARA cells were treated
with 1mM PD for 6h or a neutralising polyclonal antibody to AREG
(10mgml
 1) or PBS (C) for 24h. The mRNA was harvested from four
independent cultures and analysed by QRT-PCR. PD, P¼0.017; aAREG,
P¼0.034. (C) RWGT2 cells were incubated with PBS (C), 100ngml
 1 of
EGF or 1mgml
 1 of AREG for 2, 4 and 6h. The mRNA was harvested
from four independent cultures and analysed by QRT-PCR. Two-hour EGF,
P¼0.02; 4h EGF, P¼0.002; 4h AREG, P¼0.002; 6h EGF, P¼0.004; 6h
AREG, P¼0.001. (D) HARA cells were incubated with PBS (C),
100ngml
 1 of EGF or 1mgml
 1 of AREG for 2, 4 and 6h. The mRNA
was harvested from four independent cultures and analysed by QRT-PCR.
Four-hour AREG, P¼0.02; 6h EGF, P¼0.02; 6h AREG P¼0.013. Values
in all panels represent the mean of four samples from individual
cultures7s.e.m. These experiments were repeated three times with cells
derived from independent passages with similar results, *Po0.05 relative to
C (control). Two-tailed Student’s t-test.
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sthan the RWGT2 cells (Figure 1A). As shown in Figure 1B, both
cell lines expressed high levels of EGFR and moderate levels of the
ErbB2 receptor as detected by Western blots of concanavalin-A
(conA)-precipitated proteins. HARA cells expressed ErbB3 protein,
whereas ErbB4 immunoreactivity was barely detectable in either
cell line (Figure 1B). Both cell lines were evaluated for mRNA
expression of the EGFR ligands; AREG, HB-EGF and TGF-a by
QRT-PCR. The AREG/GAPDH mRNA ratios were two orders
greater than HB-EGF and TGF-a in both lines (Figure 1C, D). To
determine whether the EGFR was phosphorylated and active in the
cells under normal basal culture conditions, Western blots of
conA-precipitated protein extracts were probed with a general
phosphotyrosine-specific antibody, 4G10. Extracts from the
RWGT2 cells contained a phosphotyrosine immunoreactive band
that increased in intensity in the control EGF-stimulated RWGT2
cells (left panel, Figure 1E). A small amount of phosphotyrosine
immunoreactive EGFR was detected in HARA cells. Despite
expressing similar levels of EGFR and EGFR ligand RNA, the
HARA cells expressed less PTHrP mRNA in vitro than the RWGT2
cells.
The role of EGFR activation and autocrine ligand production on
PTHrP gene expression was further investigated using EGFR TKIs,
anti-EGFR and anti-AREG antibodies in both cell lines. Additional
studies evaluated the effect of EGFR ligand treatment on PTHrP
gene expression by QRT-PCR. Six-hour treatments with 1mM of the
EGFR TKI, PD, decreased the ratio of PTHrP/GAPDH mRNA by
B80% in RWGT2 cells grown in basal medium (Figure 2A). The
addition of EGFR ligand blocking and AREG neutralising
antibodies to basal culture medium reduced PTHrP/GAPDH
mRNA levels 50–65% in RWGT2, respectively (Figure 2A).
Neutralising HB-EGF and TGF-a antibodies (applied at concentra-
tions up to 10-fold greater than the AREG antibodies) failed to
reduce PTHrP mRNA levels in the RWGT2 line (data not shown).
Treatment of HARA cultures with PD and AREG neutralising
antibodies reduced PTHrP/GAPDH mRNA levels B60 and 40%,
respectively (Figure 2B). Both cell lines were treated with the EGFR
ligands, EGF (100ngml
 1) or AREG (1mgml
 1) for 2, 4 and 6h
and evaluated for PTHrP mRNA levels. Addition of exogenous
ligands increased PTHrP transcript levels up to 10-fold by 6h
(Figure 2C, D). These data support the concept that the EGFR is a
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Figure 3 Mitogen-activated protein kinase signalling mediates EGFR-induced activation of PTHrP gene expression. (A) Epidermal growth factor receptor
and ERK phosphorylation was reduced by EGFR TKI treatment in both RWGT2 and HARA cells. Upper bands are from a Western blot of conA-Sepharose
precipitated proteins probed first with the generic phosphotyrosine monoclonal antibody 4G10, then stripped and reprobed with an EGFR antibody. Lower
bands are from a Western blot of 30mg of protein probed first with a phospho-ERK 1/2 antibody, then stripped and reprobed with an antibody to ERK 1/2
and finally stripped and reprobed with an antibody to b-actin (not shown). C (control) indicates cells treated with DMSO vehicle for 6h. EGFRI indicates
cells treated with PD (1mM) for 6h. This experiment was repeated twice. (B) A MEK inhibitor significantly reduced basal PTHrP/GAPDH mRNA ratios in
both cell lines. RWGT2 and HARA cells were treated with 1mM DMSO (C), PD (EGFRI, 1mM) or PD98059 (MEKI, 10mM) for 6h. The mRNA was
harvested from four independent cultures and analysed. Two-tailed Student’s t-test. *Po0.05 relative to C (control). For the RWGT2 experiments: MEKI,
P¼0.045; EGFRI, P¼0.03; for HARA experiments: MEKI, P¼0.04; EGFRI, P¼0.04. (C, D) A MEK inhibitor blunted EGFR ligand-induced increases in
PTHrP/GAPDH mRNA ratios in both cell lines. Cells were preincubated with 1mM DMSO (C), PD (EGFRI, 1mM) or PD98059 (MEKI, 10mM) for 1h and
then stimulated with 100ngml
 1 EGF (þEGF) or 1mgml
 1 AREG (þAREG) for 6h. B represents untreated cells in all experiments. Panels B–D represent
four replicates of samples with all experiments repeated twice. Two-tailed Student’s t-test. *Po0.05 relative to C (control). (C) EGF EGFRI, P¼0.01; MEKI,
P¼0.05; AREG EGFRI, P¼0.02; MEKI, P¼0.053 not significant. (D) EGF EGFRI, P¼0.001; MEKI, P¼0.046; AREG EGFRI, P¼0.049; MEKI, P¼0.03. (E)
Basal reporter gene activity from a PTHrP-P3 construct was reduced by a dominant-negative Raf construct in both the RWGT2 and HARA cells. RLU
represents relative luciferase unit as defined in the Materials and methods. Co-transfection of the PTHrP reporter gene with the empty vector is indicated by
pcDNA3, a dominant-negative Ras construct ( ras) a dominant-negative Raf construct ( raf). Values in all panels represent the mean of four samples from
individual cultures7s.e.m. These experiments were repeated three times with cells derived from independent passages with similar results. Two-tailed
Student’s t-test. *Po0.05 relative to C (control). RWGT2: ras, P¼0.019; raf, P¼0.033; HARA: ras P¼0.02.
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cell lines.
The MAPK signalling pathway activates PTHrP gene
expression downstream of the EGFR
Several of the signalling pathways activated by EGFR converge on
the MAPK cascade. Activation of the MAPK cascade was evaluated
by examining the phosphorylation status of the downstream
MAPK (ERK1/2) in basal culture conditions and after treatment
with the EGFR TKI, PD. Six-hour treatments of both RWGT2 and
HARA cells with 1mM PD resulted in a reduction of phosphorylated
ERK1/2 as measured by Western blot without a change in the total
ERK protein levels (Figure 3A). In addition, treatment with the
MEK inhibitor, PD98059, reduced basal PTHrP mRNA levels in
both lines to similar levels found in the EGFR TKI PD-treated cells
(Figure 3B). Furthermore, treatment with the MEK inhibitor,
PD98059, blunted the EGF- and AREG-stimulated increases in
PTHrP gene expression in both lines (Figure 3C, D). Finally, co-
transfection was used to test whether a dominant-negative Ras or
Raf construct could disrupt basal expression from a human
PTHrP-P3 promoter-driven reporter gene. As shown in Figure 3E,
the dominant-negative Raf repressed reporter gene activity 50–
70% in RWGT2 and HARA cells, respectively; however, the Ras
construct only repressed reporter gene activity in the RWGT2 line.
These results demonstrated that the effect of EGFR on PTHrP gene
expression was mediated, in part, by the MAPK pathway in both
hypercalcaemia-inducing lung SCC lines.
Comparison of RWGT2 and HARA xenograft models of
hypercalcaemia
The EGFR and MAPK pathway control PTHrP mRNA expression
in both lines, however, there was a 10-fold greater level of PTHrP
mRNA in the RWGT2 line as compared to HARA cells in vitro.T o
determine if both cell lines would be suitable for future studies
with EGFR-targeted therapeutics, we compared the onset of
hypercalcaemia, plasma PTHrP concentrations, tumour PTHrP
mRNA expression and EGFR phosphorylation status in sub-
cutaneous tumours of nude mice. The HARA line produced
hypercalcaemia in less time after tumour cell injection than the
RWGT2 cells (50% of HARA mice were hypercalcaemic in 40 days
vs RWGT2 mice in which 50% of the mice were hypercalcaemic in
60 days) (Figure 4A). Moreover, the volume of the hypercalcaemia-
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Figure 4 Comparison of RWGT2 and HARA models of hypercalcaemia. (A) Kaplan–Meir analysis of time to the development of hypercalcaemia. Fifty
percent of mice developed HHM 40 days after injection of HARA cells compared to the RWGT2 xenograft mice that developed HHM 60 days after
injection of cells. P¼0.01. RWGT2 tumours (n¼18) and HARA tumours (n¼10). (B) Average tumour volume at time of hypercalcaemia. When
hypercalcaemia was diagnosed, the RWGT2 (n¼18) tumours were nearly twice as large as the HARA tumours (n¼10) *P¼0.04 HARA compared to
RWGT2. Two-tailed Student’s t-test. (C) Comparison of plasma PTHrP concentrations in hypercalcaemic untreated mice with RWGT2 and HARA
xenografts. Plasma PTHrP concentrations were determined 78h after the development of HHM in both xenograft models. Average plasma PTHrP
concentrations in the untreated mice were 80% higher (22 vs 12pM) in the HARA (n¼5) as compared to RWGT2-bearing mice (n¼8). (D) Comparison
of PTHrP mRNA expression between cells grown in vitro and in vivo. RNA was extracted from tumours that were removed 78h after hypercalcaemia was
identified. The ratio of PTHrP to GAPDH mRNA was assayed by QRT-PCR. The ratio of PTHrP to GAPDH mRNA in HARA tumours (HARA-T) was
increased 100-fold compared to HARA cells (HARA-C) grown in vitro. The ratio of PTHrP to GAPDH mRNA in HARA tumours was sixfold higher than
RWGT2 tumours (RWGT2-T). Values in all panels represent the mean of four samples from individual cultures or tumours7s.e.m. *P¼0.027 HARA
tumours relative to HARA cells;
yPo0.05 HARA tumours relative to RWGT2 tumours. The QRT-PCR was repeated twice with similar results. Two-tailed
Student’s t-test. (E) Phosphorylation of the EGFR was measured in protein extracts from RWGT2 and HARA tumours by Western blotting. The general
phosphotyrosine antibody 4G10 and polyclonal antibody for phosphorylated Tyr 992 was used to probe 1mg of extracted tumour protein precipitated with
conA-Sepharose. Blots were stripped and reprobed with EGFR antibodies. Four tumours from each cell line were evaluated.
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inducing RWGT2 tumours (Figure 4B). Plasma PTHrP concentra-
tions were B80%-fold higher (22 vs 12pM) in mice with HARA as
compared to RWGT2 xenografts. The RWGT2 cells grown in vitro
or as xenografts, produced similar PTHrP mRNA levels
(Figure 4C). In contrast, PTHrP mRNA levels were increased
nearly 100-fold in the HARA xenografts compared to cells grown
in vitro (Figure 4D). Tumour extracts from both lines had
detectable phosphorylated EGFR immunoreactivity, but RWGT2
extracts produced more intense bands (Figure 4E). Therefore, both
cell lines produced tumours with activated EGFR, secreted high
concentrations of PTHrP, and induced hypercalcaemia.
Gefitinib reduced hypercalcaemia in mice with RWGT2
and HARA xenografts
The anilinoquinazolines, gefitinib, is a highly specific EGFR TKI
that can be used in rodents and humans at high doses with
minimal toxicity (Janmaat and Giaccone, 2003). Treatment
with gefitinib (1mM) was as effective as PD (1mM) in reducing
PTHrP mRNA and EGFR/ERK phosphorylation in RWGT2 cells
(data not shown). To assess the ability of an anilinoquinazoline to
decrease plasma total calcium concentrations in vivo, RWGT2
tumour-bearing mice with HHM were administered gefitinib
(200mgkg
 1) every 24h for three treatments and plasma
total calcium concentration was measured at 6, 24, 52 and 78h
after the first treatment. The total calcium concentrations
for normal 6- to 8-week-old male nude mice ranged from
8t o1 0 m g d l
 1 (Figure 5A). Total calcium concentrations of
gefitinib-treated mice were significantly reduced at all time points
when compared to pretreatment values and untreated mice at
comparable time points (Figure 5A). The plasma total calcium
concentrations of all gefitinib-treated mice returned to baseline at
52h (P¼0.001). Moreover, when normocalcaemic nude mice
without tumours were given gefitinib (200mgkg
 1) on an identical
dosage schedule, treatment did not reduce plasma calcium
concentrations as compared to pretreatment and baseline values
(Figure 5A).
Stimulation of the PTH receptor by PTHrP activates adenylyl
cyclase in the renal tubules so we measured the effect of gefitinib
administration on urinary cAMP:creatinine ratios. Gefitinib-
treated mice with RWGT2 and HHM had a significant reduction
of urine cAMP levels at 6, 24, 52 and 78h when compared to the
control mice (P¼0.02) (Figure 5B).
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Figure 5 Gefitinib reduced plasma total calcium concentrations and urinary cAMP creatinine ratios in nude mice with RWGT2 xenografts and
hypercalcaemia. (A) Hypercalcaemic mice with RWGT2 xenografts (n¼9) were treated daily for 3 days with gefitinib (200mgkg
 1, per os (p.o.)). The first
treatment occurred at the onset of hypercalcaemia. Treatment resulted in a statistically significant decrease in total plasma calcium concentrations compared
to pretreatment values at all time points (6, 24, 52 and 78h) and compared to untreated mice (n¼8). Repeated measures one-way ANOVA, mean7s.e.m.,
*Po0.001. Normal nude mice (n¼5) were treated daily for 3 days with gefitinib (200mgkg
 1, p.o.) or untreated (n¼5). Gefitinib did not decrease total
plasma calcium concentrations compared to pretreatment values at all time points and compared to untreated mice. Repeated measures one-way ANOVA,
mean7s.e.m. *P¼0.001 relative to treated;
yP¼0.001 relative to baseline values. (B) Spontaneously voided urines were collected at the indicated times
after the first gefitinib treatment (200mgkg
 1). Cyclic AMP and creatinine concentrations were measured. The cAMP and creatinine ratio was expressed as
nMmg
 1. Mice received additional doses of gefitinib at 24 and 48h. Values at each time point represent the mean of two measurements from eight tumour-
bearing mice from both the gefitinib-treated and untreated groups, as well as, 16 nontumour-bearing mice at baseline. Cyclic AMP levels were decreased in
the gefitinib-treated mice when compared to untreated mice at all time points. Repeated measures one-way ANOVA, Mean7s.e.m., *P¼0.02 relative to
treated;
yP¼0.004 relative to baseline values. In all figures, the baseline and pretreatment groups are represented by the columns labelled base and pretreat,
respectively. (C) Plasma PTHrP concentrations were measured using plasma samples collected before tumour injection (base) and at 6 and 78h after
gefitinib or placebo treatment. Experiments included nine gefitinib-treated mice and eight untreated mice. Baseline PTHrP values were from the same1 7
mice. In the gefitinib-treated mice (black column), there was a mild reduction at 6h followed by a marked reduction (50%) in plasma PTHrP concentrations
when compared to untreated mice (white columns) at the respective time points. Untreated and gefitinib-treated mice with RWGT2 xenografts had PTHrP
concentrations that were significantly greater than baseline at both 6 and 78h. *P¼0.02 relative to treated;
yP¼0.006 relative to baseline values. (D)
Gefitinib treatment reduced PTHrP mRNA levels in RWGT2 tumours. RNA was extracted from tumours that were removed 78h after hypercalcaemia was
identified. The ratio of PTHrP to GAPDH mRNA was assayed by QRT-PCR. The ratio of PTHrP to GAPDH mRNA in the gefitinib-treated tumours (n¼6)
was decreased 60% as compared to untreated (n¼6). The QRT-PCR was repeated twice with similar results. P¼0.014.
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sThe in vivo response of PTHrP gene expression to treatment
with an EGFR TKI was evaluated by measuring plasma PTHrP
concentrations and PTHrP mRNA from tumours in hypercalcae-
mic mice with RWGT2 xenografts. Plasma samples were collected
before xenografting, 6h after the first gefitinib treatment (6h) as
well as at the end of the trial, that is, 30h after the third and final
drug administration (78h). Comparison of gefitinib- and vehicle-
treated groups revealed a trend towards decreased PTHrP
concentrations as early as 6h after the first treatment. There were
reduced PTHrP concentrations (P¼0.01) in the gefitinib-treated
mice at 78h, but the PTHrP concentrations were not decreased to
baseline values (Figure 5C). PTHrP/GAPDH mRNA ratios were
reduced B60% in tumours from treated mice at 78h (Figure 5D).
These data demonstrated that gefitinib reduced PTHrP gene
expression and circulating PTHrP concentrations in the RWGT2
model of HHM.
Epidermal growth factor receptor phosphorylation in tumours
was measured by Western blots with the EGFR phosphotyrosine-
specific antibody to residue 1068. In RWGT2 tumours harvested at
78h from treated mice, Y1068 phosphorylation was markedly
reduced compared to the RWGT2 tumour lysates from untreated
mice (Figure 6A). Phospho-ERK levels were decreased in the
tumours from treated mice as well. Differences in the tumour
volumes at the pretreatment time point were found between the
treated and untreated groups; however, there was no difference in
the tumour volume between these groups of mice at the 48 or 78h
time points (Figure 6B). No difference in final tumour weights
between treated and untreated mice were found (data not shown).
Degree of tumour cell apoptosis was measured with both TdT-
mediated dUTP nick end labelling (TUNEL) and haematoxylin and
eosin (H&E) at the 78h time point in both the treated and
untreated mice (Figure 6C). There were no differences in TUNEL
labelling indexes or apoptosis (H&E) of tumour cells in the treated
mice compared to the untreated mice (Figure 6D). The gefitinib-
mediated reduction in PTHrP mRNA and plasma concentrations
was not accompanied by a decrease in tumour volume or an
increase in tumour cell apoptosis.
In June of 2005, use of gefitinib in humans was restricted to lung
cancer patients for compassionate use only and could not be
purchased for research purposes. At this time, we possessed a
small amount of gefitinib sufficient to treat five animals. This
material was used to treat five hypercalcaemic HARA xenografts
using a dose and time course identical to that we used with the
RWGT2 cells. Total calcium concentrations were significantly
reduced by 78h (Figure 7A) (P¼0.042). Urinary cAMP creatinine
ratio averages were not significantly reduced at any time point
(data not shown). At 78h plasma PTHrP levels were significantly
reduced compared to untreated mice, but were not reduced to the
levels observed in treated mice with RWGT2 tumours (P¼0.047)
(compare Figure 5C to Figure 7B). HARA tumour PTHrP mRNA
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Figure 6 Gefitinib treatment reduced RWGT2 tumour EGFR and MAPK phosphorylation at 78h but not tumour volume. (A) Comparison of EGFR and
MAPK phosphorylation as assessed in untreated and gefitinib-treated RWGT2 tumours by Western blots. Tumours from untreated RWGT2 mice had
greater phosphorylation of both EGFR phosphotyrosine residue 1068 and ERK1/2 when compared to tumour lysates from RWGT2 gefitinib-treated mice.
Furthermore, all lysates had equivalent EGFR and ERK1/2 expression. Equal amounts of total protein (10mg) were separated by electrophoresis using 4–
20% tris-glycine sodium dodecyl sulphate-polyacrylamide gels, transferred onto nitrocellulose membranes, and analysed by immunoblotting using rabbit
polyclonal antibodies to phosphotyrosine 1068 and phospho ERK1/2. Blots were stripped and reprobed with rabbit polyclonal antibodies against EGFR and
ERK1/2. The blots were stripped a final time and reprobed with a polyclonal antibody to b-actin. Experiments were repeated three times, and the data from
a representative blot are shown. (B) Tumour volumes were measured serially as described in ‘Materials and methods.’ No reduction in tumour volume was
present (pretreatment, 48 and 78h) between gefitinib-treated and untreated mice at any time point. Each bar represents the mean tumour volume of eight
or nine mice; bars, s.e.m. *P¼0.048 vs treated at the pretreatment time point even though the animals were randomised. (C) Gefitinib treatment of mice
with RWGT2 xenografts did not cause an increase in apoptosis. Representative samples at 78h from gefitinib-treated and untreated tumours. H&E staining
revealed similar numbers of apoptotic cells represented as shrunken cells with eosinophilic cytoplasm and karyorrhectic or pyknotic nuclei in both the
treated and untreated mice (black, arrows); bar 100mm. Fluorescent TUNEL staining for apoptosis (black, arrows) revealed similar numbers of apoptotic
cells throughout the tumour parenchyma.  400. (D) Comparison of numbers of apoptotic cells in gefitinib-treated and untreated RWGT2 tumours at 78h.
Ten  100 fields from a fluorescent TUNEL slide for each mouse were counted to assess the number of apoptotic cells per field. The mean apoptotic cell
number per  100 field was represented as the black bar for gefitinib-treated and white bar for the untreated. No significant differences in mean apoptotic
cells in tumours were present between the gefitinib-treated vs untreated mice.
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slevels were decreased by 90% in the gefitinib-treated animals
(Figure 7C).
DISCUSSION
It has been known for over a decade that exogenous EGF
stimulates PTHrP gene expression in a human lung SCC and
keratinocyte lines (Tait et al, 1994; Heath et al, 1995), but it has not
been determined whether EGFR signalling contributes to cancer-
mediated syndromes such as HHM. We have established that the
EGFR ligand, AREG, stimulated EGFR signalling and PTHrP gene
expression in two human lung SCC lines that induce hypercalcae-
mia when grown in vivo. As with most lung SCCs (Salomon et al,
1995; Scagliotti et al, 2004; Prudkin and Wistuba, 2006), both
HARA and RWGT2 cells expressed abundant EGFR in vitro and in
vivo. Phosphotyrosine immunoblotting revealed that the receptor-
associated kinase was active in both lines under basal conditions.
Measurements of mRNA expression of the EGF family of ligands
showed that both cell lines expressed high levels of AREG and
modest amounts of HB-EGF and TGF-a. The coexpression of two
or more EGF-like growth factors frequently occurs in human
carcinomas (Ciardiello et al, 1991; Qi et al, 1994; Normanno et al,
2001). The ability of neutralising antibodies to AREG but not to
TGF-a or HB-EGF to reduce PTHrP transcripts in both lines
demonstrated that AREG was the primary activator of EGFR in cell
lines. In both cell lines, exogenous EGFR ligands stimulated a four-
to ninefold increase in PTHrP mRNA. Epidermal growth factor
receptor signalling was necessary and sufficient for increased
PTHrP gene expression in the HARA and RWGT2 cells. Whether
signalling by the EGFR activates PTHrP gene expression by
increasing gene transcription or message stability will be
addressed by future studies.
The MAPK pathway mediated the EGFR-induced activation in
the RWGT2 and HARA cells. Our findings are consistent with
studies that reported calcium receptor (CaR) stimulation induced
EGFR-MAPK signalling in transfected human embryonic kidney
cells, human prostate cancer cells and hypercalcaemia-inducing rat
Leydig cells (H-500) (MacLeod et al, 2003; Yano et al, 2004; Tfelt-
Hansen et al, 2005b). Blockade of the Ras-MAPK pathway with a
dominant-negative Raf construct or a MEK inhibitor (PD98059)
reduced PTHrP gene expression in H-500 cells (Aklilu et al, 2000).
A ras inhibitor, B-1086, was able to slow the growth of the H-500
tumour and prevented the formation of hypercalcaemia in vivo
(Aklilu et al, 1997, 2000). Highly specific and low toxicity
inhibitors of the MAPK pathway will likely prove useful to reduce
PTHrP gene expression in certain cancers.
Investigations on the control of PTHrP gene expression suggest
that different signalling events were responsible for the induction
of hypercalcaemia in the RWGT2 and HARA models. Previous
studies suggested that PTHrP gene expression in vitro predicted
the ability of a cell line to induce hypercalcaemia in nude mice
(Wysolmerski et al, 1996). The RWGT2 line was part of that study
and consistent with those earlier findings we determined that the
PTHrP mRNA levels in vivo were approximately equivalent to
those in the tumour (Figure 4). In contrast, HARA tumours taken
from hypercalcaemic mice demonstrated a B100-fold increase in
PTHrP mRNA levels over cells in vitro, indicating that host factors
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Figure 7 Gefitinib reduced plasma total calcium and PTHrP concentra-
tions in nude mice with HARA xenografts and hypercalcaemia. (A)
Hypercalcaemic mice with HARA xenografts (n¼5) were treated daily for
3 days with gefitinib (200mgkg
 1, p.o.). The first treatment occurred at the
onset of hypercalcaemia. Treatment resulted in a statistically significant
decrease in total plasma calcium concentrations compared to pretreatment
values at 78h and compared to untreated mice (n¼5). Repeated
measures one-way ANOVA, mean7s.e.m., *P¼0.042 relative to treated;
yP¼0.001 relative to baseline. (B) Plasma PTHrP concentrations were
measured using plasma samples collected before HARA cell injections
(baseline) and at 78h after gefitinib or placebo treatment. Experiments
included five gefitinib-treated mice and five untreated mice. Baseline PTHrP
values were from the same 10 mice. In the gefitinib-treated mice (black
column), there was a marked reduction (60%) in plasma PTHrP
concentrations when compared to untreated mice (white columns).
Untreated and gefitinib-treated mice with HARA xenografts had PTHrP
concentrations that were significantly greater than baseline at 78h.
*P¼0.047 relative to treated;
yP¼0.001 relative to baseline. (C) Gefitinib
treatment reduced PTHrP mRNA levels in RWGT2 tumours. RNA was
extracted from tumours that were removed 78h after hypercalcaemia was
identified. cDNA was produced with the MultiScribe Reverse Transcriptase
Kit (Applied Biosystems, Foster City, CA, USA) and QRT-PCR performed.
PTHrP to GAPDH mRNA was assayed by QRT-PCR. The ratio of PTHrP
to GAPDH mRNA in the gefitinib-treated tumours (n¼3) was decreased
90% as compared to untreated (n¼4). The QRT-PCR was repeated twice
with similar results. *P¼0.02.
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sactivated PTHrP gene expression. Activation of PTHrP gene
expression in vivo has been attributed to circulating factors as well
as tumour microenvironment-derived cytokines or growth factors.
Observations based on several xenograft HHM models suggest that
high plasma calcium concentrations result in CaR-mediated
activation of PTHrP production (Sanders et al, 2001; Tfelt-Hansen
et al, 2003, 2005a). In the bone microenvironment, TGF-b released
from bone at sites of osteoclastic resorption activates PTHrP
expression in metastatic cancer cells (Kakonen et al, 2002).
Tumour-associated stroma in soft tissues also produces TGF-b
(Gatza et al, 2003; Trapani, 2005). Therefore, hypercalcaemia
induced by the RWGT2 model appeals to be due to an intrinsic
capacity of the cancer cells to produce PTHrP, whereas the HARA
line induces the syndrome as a result of extrinsic stimulation of
tumour cell PTHrP gene expression.
Epidermal growth factor receptor signalling is likely to play
different roles in the control of PTHrP gene expression and
generation of hypercalcaemia by the two cell lines. RWGT2 cells in
vitro or in tumours exhibited relatively high levels of EGFR
phosphorylation (Figures 1, 4). Consistent with a central role of the
EGFR in control of PTHrP gene expression in RWGT2 cells, EGFR
TKIs substantially reduced PTHrP in vitro as well as plasma
protein levels, and this was accompanied by a rapid decrease in
serum calcium levels (Figures 2 and 5). In contrast, EGFR
phosphorylation was barely detectable in HARA tumours,
suggesting that the receptor was not active to the extent observed
in the RWGT2 line. The best understood mechanism of EGFR
activation involves the autocrine/paracrine release of the ecto-
domain of integral membrane EGFR ligand proteins (Jorissen et al,
2003). The shedding of the ectodomain involves activation of
matrix metalloproteinases and extracellular release of EGFR
ligands (Yan et al, 2002). G-protein-coupled receptors such as
the CaR, are able to transactivate EGFR through induction of the
membrane-associated matrix metalloproteinases such as ADAM-
17 (Ruhe et al, 2006). We have recently cloned and sequenced the
CaR in both the HARA and RWGT2 cells lines (data not shown),
but receptor characteristics typical of neoplastic cells such as
overexpression, constitutive activation and the presence of
activating mutations have not been evaluated. Although it is
possible that signals from the CaR or other G-protein receptors
might result in high levels of EGFR activity in the RWGT2 line, the
lack of robust EGFR phosphorylation in the HARA tumours
suggested transactivation did not account for increased PTHrP
gene expression in this model. This does not eliminate the
possibility that second messenger pathways directly coupled to
the CaR could underlie the activation of PTHrP expression in the
HARA line. The fact that gefitinib induced a decrease in the plasma
calcium levels in the HARA model suggests a role for the receptor
in activation of PTHrP gene expression in these cells. We speculate
that this might reflect a synergism of EGFR signalling with another
growth factor pathway such as TGF-b. In conclusion, autocrine
AREG stimulation of the EGFR may serve as the intrinsic factor
that drives high levels of PTHrP gene expression in the RWGT2
line, whereas this pathway appears to play a secondary role in the
extrinsic activation of the gene in HARA tumours by host factors.
The effect of gefitinib in the RWGT2 model of HHM was due in
part to direct actions on tumour cells. Gefitinib treatment reduced
EGFR phosphorylation at tyrosine 1068 and ERK phosphorylation
in the RWGT2 tumours consistent with a blockade of EGFR kinase
activity. Tumour volume, mass and cell death were not altered in
the treated mice indicating that apoptosis of the tumour cells did
not contribute to the lower PTHrP concentrations. We speculate
that blockade of EGFR-mediated activation of PTHrP gene
expression contributed to the decreased plasma protein concen-
trations in both the RWGT2 and HARA models. However, over 20
nonspecific cellular targets of gefitinib unrelated to EGFR
inhibition has been identified recently in HeLa cells using
proteomics. Therefore, we are unable to rule out the possible
contribution of additional kinase inhibition in decreasing hyper-
calcaemia in our in vitro studies (Brehmer et al, 2005).
Understanding the signalling events that regulate bone resorp-
tion has led to the development of a new generation of potential
therapies for HHM. These include the soluble decoy receptor for
RANKL, osteoprotegerin (OPG), anti-PTHrP antibodies and
bisphosphonates. A single injection of anti-PTHrP antibodies
reduced calcium and cAMP/creatinine levels near baseline levels
within hours after administration in a mouse xenograft model of
HHM (Kukreja et al, 1988) and humanised anti-PTHrP antibodies
had a similar efficacy in a nude rat xenograft model of HHM (Sato
et al, 2003; Onuma et al, 2005). One treatment with OPG reduced
plasma calcium concentrations to baseline within 24–48h in a
mouse xenograft model of HHM (Morony et al, 1999). In the above
models of HHM, treatment with the bisphosphonates, pamidro-
nate, zoledronic acid and alendronate were unable to return serum
calcium concentrations to baseline (Morony et al, 1999; Onuma
et al, 2005).
In summary, our findings support the concept that EGFR
signalling contributes to high levels of PTHrP gene expression in
lung SCCs that induce HHM. Furthermore, EGFR TKIs have the
capacity to reduce hypercalcaemia in two lung SCC models, and
their use to treat various types of non-small cell lung cancer may
prevent the development of HHM.
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